{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:11:12Z","timestamp":1793873472475,"version":"4.6.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Standard treatment for placental site trophoblastic tumor is hysterectomy. This may be unacceptable to women desiring fertility. Cells aberrant in placental site trophoblastic tumor display an ability to invade normal tissue while evading the immune system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CASE:<\/jats:title>\n            <jats:p>We present a case of a 23-year-old woman with stage I placental site trophoblastic tumor who declined hysterectomy. Tumor assay for program cell death-ligand 1 staining was performed and suggestive of an immune-responsive tumor. The patient initiated intravenous pembrolizumab 200 mg every 2 weeks, and by cycle 3 her \u03b2-hCG level fell to undetectable. She subsequently conceived and went on to have an uncomplicated term vaginal birth after cesarean. At 6 weeks postpartum, she remained without evidence of disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Immunotherapy can eliminate early program cell death-ligand 1\u2013positive placental site trophoblastic tumor with subsequent normal pregnancy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004434","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T01:02:06Z","timestamp":1624496526000},"page":"115-118","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Term Pregnancy After Complete Response of Placental Site Trophoblastic Tumor to Immunotherapy"],"prefix":"10.1097","volume":"138","author":[{"given":"Brock","family":"Polnaszek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bligard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Raghuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Stewart","family":"Massad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"eaat6114","DOI":"10.1126\/sciimmunol.aat6114","article-title":"Immune responses at the maternal-fetal interface","volume":"4","author":"Ander","year":"2019","journal-title":"Sci Immunol"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/PGP.0000000000000305","article-title":"PD-L1 expression in human placentas and gestational trophoblastic diseases","volume":"36","author":"Veras","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/ijgc-2020-001943","article-title":"Immunotherapy in gestational trophoblastic neoplasia: great times are coming","volume":"30","author":"Paulino","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"R4-20250430","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","article-title":"Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia","volume":"11390","author":"Ghorani","year":"2017","journal-title":"Lancet"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ctrv.2009.11.004","article-title":"Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors","volume":"36","author":"Azim","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/IGC.0000000000000892","article-title":"PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes","volume":"27","author":"Bolze","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"R9-20250430","first-page":"283","article-title":"Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia","volume":"57","author":"Lurain","year":"2012","journal-title":"J Reprod Med"},{"key":"R10-20250430","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1200\/JCO.20.00803","article-title":"Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase II trial","volume":"38","author":"You","year":"2020","journal-title":"J Clin Oncol"},{"key":"R11-20250430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2017.11.029","article-title":"Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: a case from the New England Trophoblastic Disease Center, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute","volume":"148","author":"Worley","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R12-20250430","first-page":"1","article-title":"Case report of a pregnancy during ipilimumab therapy","volume":"4","author":"Mehta","year":"2018","journal-title":"J Glob Oncol"},{"key":"R13-20250430","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2009.11.007","article-title":"Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors","volume":"36","author":"Azim","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"R15-20250430","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ygyno.2006.07.039","article-title":"Fertility sparing therapy in a patient with placental site trophoblastic tumor: a case report","volume":"103","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R16-20250430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-017-0502-0","article-title":"Fertility sparing strategies in patients affected by placental site trophoblastic tumor","volume":"18","author":"Chiofalo","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ygyno.2004.08.049","article-title":"Placental site trophoblastic tumor: outcome of five cases including fertility preserving management","volume":"96","author":"Machtinger","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R18-20250430","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/AOG.0000000000002474","article-title":"Maternal malignancy evaluation after discordant cell-free DNA results","volume":"131","author":"Carlson","year":"2018","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:50:00Z","timestamp":1746082200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004434","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"2021-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}